Evidence map›Paper›PMID 11390978›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2001

Dopamine receptor regulating factor, DRRF: a zinc finger transcription factor.

C K Hwang, U M D'Souza, A J Eisch, S Yajima, C H Lammers, Y Yang, S H Lee, Y M Kim, E J Nestler, M M Mouradian

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 71 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.Journal of experimental & clinical cancer research : CR · 2024
    Article
  6. Article
  7. Kruppel-like Factors in Skeletal Physiology and Pathologies.International journal of molecular sciences · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Analysis of human Ki-67 gene promoter and identification of the Sp1 binding sites for Ki-67 transcription.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2012
    Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

C K HwangGenetic Pharmacology Unit, Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1406, USA.
U M D'Souza
A J Eisch
S Yajima
C H Lammers
Y Yang
S H Lee
Y M Kim
E J Nestler
M M Mouradian
National Institute of Neurological Disorders and Stroke · USNational Institutes of Health · USThe University of Texas Southwestern Medical Center · US

Funding

MOLECULAR REGULATION OF TRANSMITTER RECEPTOR GENESZ01NS002826 · NINDS · NEUROLOGICAL DISORDERS AND STROKE · PI MOURADIAN, M. MARAL · 1991 to 2004
–
6 · The paper itself

Abstract

Dopamine receptor genes are under complex transcription control, determining their unique regional distribution in the brain. We describe here a zinc finger type transcription factor, designated dopamine receptor regulating factor (DRRF), which binds to GC and GT boxes in the D1A and D2 dopamine receptor promoters and effectively displaces Sp1 and Sp3 from these sequences. Consequently, DRRF can modulate the activity of these dopamine receptor promoters. Highest DRRF mRNA levels are found in brain with a specific regional distribution including olfactory bulb and tubercle, nucleus accumbens, striatum, hippocampus, amygdala, and frontal cortex. Many of these brain regions also express abundant levels of various dopamine receptors. In vivo, DRRF itself can be regulated by manipulations of dopaminergic transmission. Mice treated with drugs that increase extracellular striatal dopamine levels (cocaine), block dopamine receptors (haloperidol), or destroy dopamine terminals (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) show significant alterations in DRRF mRNA. The latter observations provide a basis for dopamine receptor regulation after these manipulations. We conclude that DRRF is important for modulating dopaminergic transmission in the brain.

Indexed as

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAmino Acid SequenceAnimalsAutoradiographyBrainCell LineCocaineConserved SequenceCorpus StriatumDopamineDopamine AntagonistsDown-RegulationGene Expression RegulationHaloperidolIn Situ HybridizationKruppel-Like Transcription Factors1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineCocaineDopamineDopamine AntagonistsHaloperidolKlf16 protein, mouseKruppel-Like Transcription FactorsReceptors, DopamineRNA, MessengerTranscription Factors

Identifiers

PMID11390978
PMCPMC34707
OpenAlexW1989085485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.